ClinicalTrials.gg
CompletedNCT02796651Updated Feb 7, 2018Results posted

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

A Phase 2 interventional study of Formoterol fumarate (6 μg) and Formoterol furmarate (20 μg) in Chronic Obstructive Pulmonary Disease - COPD, sponsored by AstraZeneca. Completed at 20 sites in United States. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-02-07.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
43rd of 89
132 · median 120
Started
2016
with 8 others
Phase 2
12 of 89
none open now
Registered
70th of 89
by date
Lead sponsor
20 of 89
AstraZeneca

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 43rd largest by enrollment, is one of 9 that started in 2016, is one of 12 in phase 2, and was the 70th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).

Read the detailed description

This is a prospective, randomized, double-blind, 5-period incomplete unbalanced crossover, placebo and active comparator (open-label) controlled, multicenter clinical trial to assess the efficacy and safety of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label formoterol fumarate (20 μg BID and 40 μg single dose) administered as an inhalation solution via a standard jet nebulizer (with a mouthpiece) connected to an air compressor (Perforomist® Inhalation Solution). The drug product is an inhalation powder comprising of micronized aclidinium bromide and micronized formoterol fumarate with α-lactose monohydrate as the carrier, presented in a breathactuated device-metered dry-powder inhaler (DPI). It has been approved under the trademarks of Genuair® and/or Pressair® in some territories.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease - COPD

Keywords

  • Perforomist
  • Pressair
  • COPD
  • Cigarette smoking
  • Formoterol fumarate
  • long-acting β2-adrenergic agonists (LABA)
  • long-acting muscarinic antagonists (LAMA)
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or non-pregnant, non-lactating female patients aged ≥40.
  • Patients with a diagnosis of (GOLD guidelines, 2016) for a period of at least 6 months prior to Visit 1.
  • Patients with moderate to severe stable COPD: post-bronchodilator ≥ 30% and \<80% of the predicted normal and post-bronchodilator FEV1/FVC \< 70% at Visit 1.
  • Patients with reversible airway obstruction defined as an increase in FEV1 of at least 12% and 200 mL over the baseline value after four inhalations of albuterol sulfate 108 µg via a pMDI at Visit 1.
  • Current or former-smokers, with a smoking history of ≥ 10 pack-years.
  • Patients able to perform acceptable and repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1.
  • Patients eligible and able to participate in the study and who had signed an Form prior to initiation of any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with asthma.
  • Any respiratory tract infection (including the upper respiratory tract) or exacerbation (including the mild COPD exacerbation) within 6 weeks prior to Visit 1 or during the run-in period.
  • Patients hospitalized for a COPD exacerbation (an emergency room visit for longer than 24 hours is considered a hospitalization) within 3 months prior to Visit 1.
  • respiratory conditions other than COPD.
  • Patients who in the investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to Visit 1.
  • Use of long-term oxygen therapy (≥ 15 hours/day).
  • Patients who do not maintain regular day/night, waking/sleeping cycles including night shift workers.
  • Clinically significant cardiovascular conditions.
  • Patients with uncontrolled Type I or Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled hypertension.
  • Patients with history of long syndrome or whose QTc (calculated according to Fridericia's Formula QTc=QT/RR1/3) > 470 ms as indicated in the centralized reading report assessed at Visit 1.
  • Patients with clinically significant abnormalities in the laboratory tests, parameters (other than QTc) or in the physical examination at Visit 1 that might compromise patient safety.
  • Patients with a history of reaction to an inhaled medication or any component thereof, including paradoxical bronchospasm.
  • Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention or symptomatic unstable prostate hypertrophy.
  • History of of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
  • Patients with any other serious or uncontrolled physical or mental dysfunction.
  • Patients with a history (within 2 years prior to screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment.
  • Patients unlikely to be cooperative or who cannot comply with the study procedures.
  • Patients treated with any drug within 30 days (or 6 half-lives, whichever is longer) prior to Visit 1.
  • Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required for a particular prohibited medication.
  • Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients.
  • Any other conditions that, in the investigator's opinion, might render the patient to be unsuitable for the study.
  • Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or sponsor.
  • Previous randomization in the present study D6571C00002.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Formoterol 6 μg

    Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).

    Drug: Formoterol fumarate (6 μg)

  • Experimental
    Formoterol 12 μg

    Participants received formoterol fumarate 12 μg administered via Pressair BID.

    Drug: Formoterol fumarate (12 μg)

  • Experimental
    Formoterol 24 μg

    Participants received formoterol fumarate 24 μg administered via Pressair BID.

    Drug: Formoterol fumarate (12 μg)

  • Placebo comparator
    Placebo

    Participants received placebo to formoterol fumarate administered via Pressair BID.

    Drug: Placebo for formoterol fumarate

  • Experimental
    Formoterol 20 μg

    Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.

    Drug: Formoterol furmarate (20 μg)

  • Experimental
    Formoterol 40 μg

    Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.

    Drug: Formoterol fumarate (40 μg)

Interventions

  • Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

    Also known as: Formoterol (Pressair®)

  • DrugFormoterol furmarate (20 μg)

    Oral Inhalation (via a standard jet nebulizer connected to an air compressor.

    Also known as: Perforomist® Inhalation Solution

  • DrugPlacebo for formoterol fumarate

    Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

    Also known as: Placebo (Pressair®)

  • Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

    Also known as: Formoterol (Pressair®)

  • Oral Inhalation (via a standard jet nebulizer connected to an air compressor.

    Also known as: Perforomist® Inhalation Solution

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug Administration, AUC0-12/12h at Day 7 on Treatment

    To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate(20 μg). Pre-dose spirometry was performed before the morning daily dose at Day 1 and Day 7 of each treatment period. Two sets of measurements were performed during the hour preceding the scheduled morning study drug administration, allowing approximately 30 minutes between them. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.

    Time frame: Day 7: 30 min, 1 to 4 hours, 6 hours, 9 hours and 12 hours post-dose

Secondary outcomes

  1. Change From Baseline in FEV1 AUC0-6/6h at Day 1 on Treatment

    To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg and 40 μg). 6-hour serial spirometry was performed at Day 1 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose.

    Time frame: Day 1: zero time to 6 hours post-dose

  2. Change From Baseline in FEV1 AUC0-6/6h at Day 7 on Treatment

    To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). 6-hour serial spirometry was performed at Day 7 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation

    Time frame: Day 7: zero time to 6 hours post-dose

  3. Change From Baseline in Morning Pre-dose (Trough) FEV1 at Day 7 on Treatment

    To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). Trough value was defined as the mean of the 2 pre-dose measurements on Day 7. If 1 of the 2 measurements was missing, the non-missing measurement was used as the trough value. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.

    Time frame: At baseline and Day 7

07

Results

Posted Feb 7, 2018

Participant flow

This study was carried on 132 participants with moderate to severe chronic obstructive pulmonary disease (COPD) \& reversible airway disease in the United States of America (USA; 21 sites) \& were randomized to one of treatment sequences (each with 5 periods of different treatment, separated by wash-out period of 7 (+/1) days after treatment period).

Participant flow — Overall Study
MilestoneTotal Participants
Started132
Formoterol fumarate (ff) 6 μg107
Formoterol fumarate (ff) 12 μg121
Formoterol fumarate (ff) 24 μg105
Perforomist 20 μg118
Perforomist 40 μg108
Placebo (lactose monohydrate)38
Completed106
Not completed26
Withdrew: Adverse event6
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject4
Withdrew: Protocol violation4
Withdrew: Lack of efficacy1
Withdrew: Other10

Outcome measures

PrimaryChange From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug Administration, AUC0-12/12h at Day 7 on Treatment

To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate(20 μg). Pre-dose spirometry was performed before the morning daily dose at Day 1 and Day 7 of each treatment period. Two sets of measurements were performed during the hour preceding the scheduled morning study drug administration, allowing approximately 30 minutes between them. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.

Time frame:
Day 7: 30 min, 1 to 4 hours, 6 hours, 9 hours and 12 hours post-dose
Reported as:
Least squares mean · Litre/Hour
Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug Administration, AUC0-12/12h at Day 7 on Treatment
Litre/HourFormoterol Fumarate 6 μgFormoterol Fumarate (FF) 12 μgFormoterol Fumarate (FF) 24 μgPerforomist 20 μgPlacebo (Lactose Monohydrate)
Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug Administration, AUC0-12/12h at Day 7 on Treatment0.108 (0.073 to 0.143)0.117 (0.082 to 0.151)0.161 (0.125 to 0.197)0.122 (0.087 to 0.156)0.000 (-0.055 to 0.054)
Statistical analysis
  • Formoterol Fumarate 6 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.108 · 95% CI 0.055 to 0.161
  • Formoterol Fumarate (FF) 12 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.117 · 95% CI 0.064 to 0.171
  • Formoterol Fumarate (FF) 24 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.162 · 95% CI 0.107 to 0.216
  • Perforomist 20 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.122 · 95% CI 0.069 to 0.175
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 12 μg · Mixed Models Analysis · p = 0.556 · Lsmean difference: 0.009 · 95% CI -0.021 to 0.039
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = 0.001 · Lsmean difference: 0.053 · 95% CI 0.021 to 0.085
  • Formoterol Fumarate 6 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.365 · Lsmean difference: 0.014 · 95% CI -0.016 to 0.044
  • Formoterol Fumarate (FF) 12 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = 0.006 · Lsmean difference: 0.044 · 95% CI 0.013 to 0.076
  • Formoterol Fumarate (FF) 12 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.756 · Lsmean difference: 0.005 · 95% CI -0.026 to 0.036
  • Formoterol Fumarate (FF) 24 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.014 · Lsmean difference: -0.039 · 95% CI -0.071 to -0.008
SecondaryChange From Baseline in FEV1 AUC0-6/6h at Day 1 on Treatment

To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg and 40 μg). 6-hour serial spirometry was performed at Day 1 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose.

Time frame:
Day 1: zero time to 6 hours post-dose
Reported as:
Least squares mean · Litre/Hour
Change From Baseline in FEV1 AUC0-6/6h at Day 1 on Treatment
Litre/HourFormoterol Fumarate 6 μgFormoterol Fumarate (FF) 12 μgFormoterol Fumarate (FF) 24 μgPerforomist 20 μgPerforomist 40 μgPlacebo (Lactose Monohydrate)
Change From Baseline in FEV1 AUC0-6/6h at Day 1 on Treatment0.111 (0.077 to 0.145)0.148 (0.115 to 0.182)0.205 (0.171 to 0.239)0.195 (0.162 to 0.229)0.246 (0.212 to 0.280)-0.019 (-0.063 to 0.025)
Statistical analysis
  • Formoterol Fumarate 6 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.130 · 95% CI 0.091 to 0.169
  • Formoterol Fumarate (FF) 12 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.167 · 95% CI 0.128 to 0.206
  • Formoterol Fumarate (FF) 24 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.224 · 95% CI 0.184 to 0.263
  • Perforomist 20 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.214 · 95% CI 0.176 to 0.253
  • Perforomist 40 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.265 · 95% CI 0.226 to 0.304
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 12 μg · Mixed Models Analysis · p = 0.004 · Lsmean difference: 0.037 · 95% CI 0.012 to 0.062
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.094 · 95% CI 0.068 to 0.119
  • Formoterol Fumarate 6 μg vs Perforomist 20 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.084 · 95% CI 0.059 to 0.110
  • Formoterol Fumarate 6 μg vs Perforomist 40 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.135 · 95% CI 0.109 to 0.161
  • Formoterol Fumarate (FF) 12 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.057 · 95% CI 0.031 to 0.082
  • Formoterol Fumarate (FF) 12 μg vs Perforomist 20 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.047 · 95% CI 0.023 to 0.071
  • Formoterol Fumarate (FF) 12 μg vs Perforomist 40 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.098 · 95% CI 0.073 to 0.123
  • Formoterol Fumarate (FF) 24 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.469 · Lsmean difference: -0.009 · 95% CI -0.035 to 0.016
  • Formoterol Fumarate (FF) 24 μg vs Perforomist 40 μg · Mixed Models Analysis · p = 0.002 · Lsmean difference: 0.041 · 95% CI 0.015 to 0.068
  • Perforomist 20 μg vs Perforomist 40 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.051 · 95% CI 0.025 to 0.076
SecondaryChange From Baseline in FEV1 AUC0-6/6h at Day 7 on Treatment

To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). 6-hour serial spirometry was performed at Day 7 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation

Time frame:
Day 7: zero time to 6 hours post-dose
Reported as:
Least squares mean · Litre/Hour
Change From Baseline in FEV1 AUC0-6/6h at Day 7 on Treatment
Litre/HourFormoterol Fumarate 6 μgFormoterol Fumarate (FF) 12 μgFormoterol Fumarate (FF) 24 μgPerforomist 20 μgPlacebo (Lactose Monohydrate)
Change From Baseline in FEV1 AUC0-6/6h at Day 7 on Treatment0.166 (0.127 to 0.205)0.177 (0.139 to 0.215)0.225 (0.186 to 0.265)0.186 (0.147 to 0.225)0.007 (-0.050 to 0.064)
Statistical analysis
  • Formoterol Fumarate 6 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.159 · 95% CI 0.105 to 0.213
  • Formoterol Fumarate (FF) 12 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.170 · 95% CI 0.116 to 0.224
  • Formoterol Fumarate (FF) 24 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.219 · 95% CI 0.163 to 0.274
  • Perforomist 20 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.179 · 95% CI 0.125 to 0.233
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 12 μg · Mixed Models Analysis · p = 0.488 · Lsmean difference: 0.011 · 95% CI -0.020 to 0.042
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = <0.001 · Lsmean difference: 0.060 · 95% CI 0.027 to 0.092
  • Formoterol Fumarate 6 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.206 · Lsmean difference: 0.020 · 95% CI -0.011 to 0.051
  • Formoterol Fumarate (FF) 12 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = 0.004 · Lsmean difference: 0.049 · 95% CI 0.016 to 0.081
  • Formoterol Fumarate (FF) 12 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.567 · Lsmean difference: 0.009 · 95% CI -0.022 to 0.041
  • Formoterol Fumarate (FF) 24 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.017 · Lsmean difference: -0.039 · 95% CI -0.072 to -0.007
SecondaryChange From Baseline in Morning Pre-dose (Trough) FEV1 at Day 7 on Treatment

To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). Trough value was defined as the mean of the 2 pre-dose measurements on Day 7. If 1 of the 2 measurements was missing, the non-missing measurement was used as the trough value. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.

Time frame:
At baseline and Day 7
Reported as:
Least squares mean · Litre
Change From Baseline in Morning Pre-dose (Trough) FEV1 at Day 7 on Treatment
LitreFormoterol Fumarate 6 μgFormoterol Fumarate (FF) 12 μgFormoterol Fumarate (FF) 24 μgPerforomist 20 μgPlacebo (Lactose Monohydrate)
Change From Baseline in Morning Pre-dose (Trough) FEV1 at Day 7 on Treatment0.077 (0.044 to 0.109)0.067 (0.035 to 0.098)0.102 (0.069 to 0.135)0.061 (0.029 to 0.092)0.002 (-0.059 to 0.063)
Statistical analysis
  • Formoterol Fumarate 6 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = 0.027 · Lsmean difference: 0.075 · 95% CI 0.008 to 0.141
  • Formoterol Fumarate (FF) 12 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = 0.054 · Lsmean difference: 0.065 · 95% CI -0.001 to 0.131
  • Formoterol Fumarate (FF) 24 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = 0.004 · Lsmean difference: 0.100 · 95% CI 0.032 to 0.168
  • Perforomist 20 μg vs Placebo (Lactose Monohydrate) · Mixed Models Analysis · p = 0.075 · Lsmean difference: 0.059 · 95% CI -0.006 to 0.123
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 12 μg · Mixed Models Analysis · p = 0.615 · Lsmean difference: -0.010 · 95% CI -0.048 to 0.028
  • Formoterol Fumarate 6 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = 0.209 · Lsmean difference: 0.025 · 95% CI -0.014 to 0.065
  • Formoterol Fumarate 6 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.403 · Lsmean difference: -0.016 · 95% CI -0.053 to 0.022
  • Formoterol Fumarate (FF) 12 μg vs Formoterol Fumarate (FF) 24 μg · Mixed Models Analysis · p = 0.074 · Lsmean difference: 0.035 · 95% CI -0.003 to 0.074
  • Formoterol Fumarate (FF) 12 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.750 · Lsmean difference: -0.006 · 95% CI -0.045 to 0.032
  • Formoterol Fumarate (FF) 24 μg vs Perforomist 20 μg · Mixed Models Analysis · p = 0.035 · Lsmean difference: -0.041 · 95% CI -0.080 to -0.003

Adverse events

Collected over From the time of signature of informed consent throughout the treatment period and including the follow-up period (i.e. 2 weeks after the last IP).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Formoterol Fumarate 6 μg0/107 (0%)1/107 (0.9%)3/107 (2.8%)
Formoterol Fumarate (FF) 12 μg1/121 (0.8%)2/121 (1.7%)4/121 (3.3%)
Formoterol Fumarate (FF) 24 μg0/105 (0%)0/105 (0%)1/105 (1%)
Perforomist 20 μg0/118 (0%)0/118 (0%)7/118 (5.9%)
Perforomist 40 μg0/109 (0%)1/109 (0.9%)0/109 (0%)
Placebo (Lactose Monohydrate)0/38 (0%)1/38 (2.6%)3/38 (7.9%)
Most frequent serious events
Most frequent serious events
EventFormoterol Fumarate 6 μgFormoterol Fumarate (FF) 12 μgFormoterol Fumarate (FF) 24 μgPerforomist 20 μgPerforomist 40 μgPlacebo (Lactose Monohydrate)
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1070/1210/1050/1180/1091/38
Multiple injuriesInjury, poisoning and procedural complications1/1070/1210/1050/1180/1090/38
Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1070/1210/1050/1181/1090/38
Myocardial infarctionCardiac disorders0/1071/1210/1050/1180/1090/38
Vascular stent occlusionGeneral disorders0/1071/1210/1050/1180/1090/38
Most frequent other events
Most frequent other events
EventFormoterol Fumarate 6 μgFormoterol Fumarate (FF) 12 μgFormoterol Fumarate (FF) 24 μgPerforomist 20 μgPerforomist 40 μgPlacebo (Lactose Monohydrate)
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1070/1210/1050/1180/1093/38
HeadacheNervous system disorders0/1073/1211/1052/1180/1090/38
Urinary tract infectionInfections and infestations2/1071/1210/1051/1180/1090/38
Upper respiratory tract infectionInfections and infestations1/1070/1210/1052/1180/1090/38
Muscle spasmsMusculoskeletal and connective tissue disorders0/1070/1210/1052/1180/1090/38

Baseline characteristics

The ITT analysis set: Consisted of all randomized participants who received at least 1 dose of investigational product (IP) and had a baseline FEV1 value and at least 1 post-baseline FEV1 measurement, regardless of a participant's adherence to the randomized treatment.

Age, Continuous
Age, Continuous(Years)Overall Study Total
Mean62.3 ± 7.5
Age, Customized
Age, Customized(Participants)Overall Study Total
<50 years5
≥50 to <65 years78
≥65 years48
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Total
Female66
Male65
08

Study locations

20 sites
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Phoenix, Arizona 85006, United States
  • Research Site
    Tempe, Arizona 85283, United States
  • Research Site
    Celebration, Florida 34747, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Portland, Oregon 97202, United States
  • Research Site
    Easley, South Carolina 29640, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Rock Hill, South Carolina 29372, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    Killeen, Texas 76543, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Dec 2016, 5 months.

Results were first posted in Feb 2018, 1 year 2 months after primary completion.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2016
First posted
Jun 13, 2016
StartActual
Jun 30, 2016
Primary completionActual
Dec 7, 2016
CompletionActual
Dec 7, 2016
Results first posted
Feb 7, 2018
Last update
Feb 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02796651
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jun 13, 2016
Start date
Jun 30, 2016
Primary completion
Dec 7, 2016
Completion
Dec 7, 2016
Results posted
Feb 7, 2018
Last update
Feb 7, 2018

Study contacts

Mark H. Gotfried, MD
principal investigator · 1112 East McDowell Road, Phoenix, AZ 85006, United States.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion